SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
PhaseBio Pharmaceuticals, Inc. (PHASQ) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 30/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — PHASQ
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.00
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.74 |
$0.00 |
$-9.22M |
- |
| 2017 |
$-0.91 |
$0.00 |
$-10.25M |
- |
| 2018 |
$-4.49 |
$668K |
$-23.85M |
-3569.8% |
| 2019 |
$-1.43 |
$2.36M |
$-39.25M |
-1662.3% |
| 2020 |
$-3.39 |
$320K |
$-98.57M |
-30801.6% |
| 2021 |
$0.00 |
$10.83K |
$-131.07K |
-1210.1% |
